Great Tree Pharmacy Toekomstige groei

Future criteriumcontroles 2/6

Great Tree Pharmacy zal naar verwachting groeien in winst en omzet met respectievelijk 14.4% en 12.2% per jaar. De winst per aandeel zal naar verwachting groeien met 15.7% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 22.8% zijn.

Belangrijke informatie

14.4%

Groei van de winst

15.7%

Groei van de winst per aandeel

Consumer Retailing winstgroei	19.4%
Inkomstengroei	12.2%
Toekomstig rendement op eigen vermogen	22.8%
Dekking van analisten	Low
Laatst bijgewerkt	22 Aug 2024

Recente toekomstige groei-updates

Recent updates

There Are Reasons To Feel Uneasy About Great Tree Pharmacy's (GTSM:6469) Returns On Capital

Mar 24

Is Great Tree Pharmacy (GTSM:6469) A Risky Investment?

Mar 03

Is Great Tree Pharmacy Co., Ltd.'s (GTSM:6469) Stock's Recent Performance A Reflection Of Its Financial Health?

Feb 09

Great Tree Pharmacy's (GTSM:6469) Earnings Are Growing But Is There More To The Story?

Jan 19

Did You Miss Great Tree Pharmacy's (GTSM:6469) 71% Share Price Gain?

Dec 28

Should We Be Excited About The Trends Of Returns At Great Tree Pharmacy (GTSM:6469)?

Dec 09

Winst- en omzetgroeiprognoses

TPEX:6469 - Toekomstschattingen van analisten en financiële gegevens uit het verleden (TWD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	22,409	963	1,049	1,249	3
12/31/2025	20,105	826	763	1,123	3
12/31/2024	17,384	713	-536	1,020	2
6/30/2024	16,690	681	998	1,378	N/A
3/31/2024	16,536	678	1,019	1,374	N/A
12/31/2023	16,144	666	564	890	N/A
9/30/2023	15,735	655	649	971	N/A
6/30/2023	15,294	661	108	433	N/A
3/31/2023	15,185	739	535	830	N/A
12/31/2022	14,565	700	911	1,227	N/A
9/30/2022	13,827	644	889	1,146	N/A
6/30/2022	13,124	580	1,164	1,441	N/A
3/31/2022	11,993	454	688	964	N/A
12/31/2021	11,281	407	823	1,078	N/A
9/30/2021	10,617	354	819	1,091	N/A
6/30/2021	9,954	295	820	1,042	N/A
3/31/2021	9,108	220	494	736	N/A
12/31/2020	8,641	194	477	728	N/A
9/30/2020	8,079	171	126	420	N/A
6/30/2020	7,540	163	-88	214	N/A
3/31/2020	7,137	156	-57	246	N/A
12/31/2019	6,602	136	-54	225	N/A
9/30/2019	6,170	134	108	341	N/A
6/30/2019	5,727	124	-2	246	N/A
3/31/2019	5,296	109	68	277	N/A
12/31/2018	4,901	106	-51	131	N/A
9/30/2018	4,503	104	17	180	N/A
6/30/2018	4,173	107	122	252	N/A
3/31/2018	3,889	107	N/A	147	N/A
12/31/2017	3,624	102	N/A	157	N/A
9/30/2017	3,420	96	N/A	62	N/A
6/30/2017	3,192	92	N/A	127	N/A
3/31/2017	2,983	90	N/A	64	N/A
12/31/2016	2,802	93	N/A	129	N/A
9/30/2016	2,615	101	N/A	107	N/A
6/30/2016	2,465	94	N/A	25	N/A
3/31/2016	2,317	91	N/A	76	N/A
12/31/2015	2,160	77	N/A	-3	N/A
9/30/2015	2,047	83	N/A	11	N/A
6/30/2015	1,919	79	N/A	-14	N/A
3/31/2015	1,774	82	N/A	-17	N/A
12/31/2014	1,662	96	N/A	95	N/A
9/30/2014	1,473	75	N/A	55	N/A
6/30/2014	1,349	80	N/A	74	N/A
3/31/2014	1,242	74	N/A	64	N/A
12/31/2013	1,136	68	N/A	55	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei 6469 ( 14.4% per jaar) ligt boven de spaarquote ( 1.1% ).

Winst versus markt: De winst van 6469 ( 14.4% per jaar) zal naar verwachting langzamer groeien dan de markt TW ( 19.9% per jaar).

Hoge groeiwinsten: De winst van 6469 zal naar verwachting groeien, maar niet aanzienlijk.

Omzet versus markt: De omzet van 6469 ( 12.2% per jaar) zal naar verwachting langzamer groeien dan de markt TW ( 12.8% per jaar).

Hoge groei-inkomsten: De omzet van 6469 ( 12.2% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen 6469 zal naar verwachting over 3 jaar hoog zijn ( 22.8 %)

Great Tree Pharmacy Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus EPS estimates fall by 13%

Consensus EPS estimates fall by 18%

Price target increased by 7.6% to NT$324

Consensus forecasts updated

Recent updates

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: EPS: NT$1.29 (vs NT$1.29 in 2Q 2023)

Great Tree Pharmacy Co., Ltd. to Report Q2, 2024 Results on Aug 09, 2024

Upcoming dividend of NT$3.60 per share

Dividend of NT$3.60 announced

Great Tree Pharmacy Co., Ltd. Announces Cash Dividend , Payable on July 31, 2024

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 13%

Great Tree Pharmacy Co., Ltd. to Report Q1, 2024 Results on May 10, 2024

Less than half of directors are independent

Full year 2023 earnings: EPS and revenues miss analyst expectations

Great Tree Pharmacy Co., Ltd. announced a financing transaction

New minor risk - Shareholder dilution

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Earnings quality

Great Tree Pharmacy Co., Ltd. Announces Convener of Audit Committee Changes

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 18%

Upcoming dividend of NT$4.70 per share at 1.3% yield

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Great Tree Pharmacy Co., Ltd. Announces Cash Dividend for the Year 2022, Payable on July 28, 2023

Great Tree Pharmacy Co., Ltd. Appoints Min-Hsiung Pan as Member of the Audit Committee and the Remuneration Committee

Great Tree Pharmacy Co., Ltd. Elects Min-Hsiung Pan as Independent Director

Now 23% undervalued

Full year 2022 earnings: EPS misses analyst expectations

Price target increased by 7.6% to NT$324

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

Great Tree Pharmacy Co., Ltd. announced that it has received TWD 220 million in funding from Sugi Holdings Co.,Ltd.

Great Tree Pharmacy Co., Ltd. announced that it expects to receive funding from Sugi Holdings Co.,Ltd.

Consensus forecasts updated

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Investor sentiment improved over the past week

Upcoming dividend of NT$2.57 per share

Great Tree Pharmacy Co., Ltd. Announces Cash Dividend, Payable on July 21, 2022

Investor sentiment improved over the past week

Less than half of directors are independent

First quarter 2022 earnings released: EPS: NT$1.67 (vs NT$1.04 in 1Q 2021)

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution for the Year Ended December 31, 2021

Great Tree Pharmacy Co., Ltd., Annual General Meeting, May 31, 2022

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS NT$1.51 (vs NT$0.66 in 3Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS NT$2.20 (vs NT$0.86 in 2Q 2020)

Investor sentiment improved over the past week

Upcoming dividend of NT$0.99 per share

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS NT$1.34 (vs NT$0.92 in 1Q 2020)

Investor sentiment improved over the past week

There Are Reasons To Feel Uneasy About Great Tree Pharmacy's (GTSM:6469) Returns On Capital

Great Tree Pharmacy Co., Ltd. Approves Dividend Distribution

Great Tree Pharmacy Co., Ltd., Annual General Meeting, Jun 24, 2021

Full year 2020 earnings released: EPS NT$3.73 (vs NT$2.77 in FY 2019)

New 90-day high: NT$101

Is Great Tree Pharmacy (GTSM:6469) A Risky Investment?

Is Great Tree Pharmacy Co., Ltd.'s (GTSM:6469) Stock's Recent Performance A Reflection Of Its Financial Health?

Great Tree Pharmacy's (GTSM:6469) Earnings Are Growing But Is There More To The Story?

Did You Miss Great Tree Pharmacy's (GTSM:6469) 71% Share Price Gain?

Should We Be Excited About The Trends Of Returns At Great Tree Pharmacy (GTSM:6469)?

New 90-day high: NT$100.00

Third quarter 2020 earnings released: EPS NT$0.86

New 90-day high - NT$94.50

First half earnings released

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen